Molecular tools for manufacturing anti-CD33 antibodies and fragments
The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.
1. An isolated polynucleotide encoding an antibody or epitope-binding fragment thereof, said antibody comprising at least six complementarity-determining regions having the amino acid sequences of SEQ ID NOs:1-6, wherein said antibody binds CD33.
2. An isolated polynucleotide encoding an antibody or epitope-binding fragment thereof, said antibody having the ability to bind CD33, comprising at least one heavy chain variable region and at least one light chain variable region, wherein said heavy chain variable region comprises three complementarity-determining regions having amino acid sequences represented by SEQ ID NOs:1-3, and wherein said light chain variable region comprises three complementarity-determining regions having amino acid sequences represented by SEQ ID NOs:4-6.
3. An isolated polynucleotide or fragment thereof comprising a nucleic acid sequence encoding the amino acid sequence SEQ ID NO: 7 and SEQ ID NOs:4-6.
4. An isolated polynucleotide or fragment thereof comprising a nucleic acid sequence encoding the amino acid sequences of SEQ ID NOs:4-6 and a polypeptide having at least 95% sequence identity to SEQ ID NO:7, wherein said polypeptide complementarity-determining regions are unchanged.
5. An isolated polynucleotide or fragment thereof comprising a nucleic acid sequence encoding the amino acid sequence SEQ ID NO: 8 and SEQ ID NOs:1-3.
6. An isolated polynucleotide or fragment thereof, comprising a nucleic acid sequence encoding the amino acid sequences of SEQ ID NOs:4-6 and a polypeptide having at least 95% sequence identity to SEQ ID NO:8, wherein said polypeptide complementarity-determining regions are unchanged.
7. An isolated polynucleotide or fragment thereof, comprising a nucleic acid sequence encoding the amino acid sequences of SEQ ID NOs:4-6 and the amino acid sequence SEQ ID NO: 9.
8. An isolated polynucleotide or fragment thereof, comprising a nucleic acid sequence encoding the amino acid sequences of SEQ ID NOs:4-6 and a polypeptide having at least 95% sequence identity to SEQ ID NO:9, wherein said polypeptide complementarity-determining regions are unchanged.
9. An isolated polynucleotide or fragment thereof comprising a nucleic acid sequence encoding the amino acid sequences of SEQ ID NOs:1-3 and the amino acid sequence SEQ ID NO: 10.
10. An isolated polynucleotide or fragment thereof, comprising a nucleic acid sequence encoding the amino acid sequences of SEQ ID NOs:1-3 and a polypeptide having at least 95% sequence identity to SEQ ID NO:10, wherein said polypeptide complementarity-determining regions are unchanged.
11. A vector comprising the polynucleotide of any one of claims 1 - 2 and 3 - 10 .
12. The vector of claim 11 , wherein said vector is an expression vector capable of expressing said antibody or antibody fragment.
13. A genetic construct comprising the polynucleotide of any one of claims 1 - 2 and 3 - 10 operatively linked to a promoter sequence and to a polyadenylation signal sequence.
14. The expression vector of claim 12 , further comprising viral DNA or bacterial DNA.
15. The expression vector of claim 12 , wherein said viral DNA is selected from the group consisting of adenoviral DNA or retroviral DNA.
16. The expression vector of claim 12 , wherein at least a portion of the vector comprises adenoviral DNA.
17. An isolated host cell comprising an expression vector of claim 12 .
18. The host cell of claim 17 , wherein said cell is a CHO cell, an E. coli , or a yeast cell.
19. A method for producing an antibody or epitope-binding fragment thereof having the ability to bind CD33, said method comprising (a) culturing a host cell as claimed in claim 17 under conditions such that said host cell expresses the antibody or epitope-binding fragment, and (b) collecting the antibody or epitope-binding fragment so expressed.
20. A method for producing an antibody or epitope-binding fragment thereof having the ability to bind CD33, said method consisting essentially of (a) culturing at least one host cell as claimed in claim 17 under conditions such that said host cell expresses at least one antibody or epitope-binding fragment, and (b) collecting the antibody or epitope-binding fragment so expressed.